You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》榮昌生物(09995.HK)暗盤平開報52.1元 現升逾6%
阿思達克 11-06 16:22
根據輝立交易平台顯示,下周一(9日)掛牌的榮昌生物製藥(09995.HK)暗盤平開報52.1元,最低見50元獲承接,掉頭高見55.6元,現造55.3元,較上市價52.1元,高6.1%,成交105萬股。

榮昌是內地一家正在進入商業化階段的生物製藥公司,其致力於發現、開發和商業化創新的、有特色的生物藥,用於治療中國乃至全球多種醫療需求未被滿足自身免疫、腫瘤科和眼科疾病。是次來港上市共發售7,653.7萬股H股,並已引入包括富達基金、貝萊德、GIC及中生製藥(01177.HK)等19名基石投資者,合共認購3,383.95萬股;其中10%公開發售獲52.4倍超購,已啟動回撥機制佔比增至40%,認購一手中籤率90%;股份以招股範圍(50.3-52.1元)上限定價,料集資淨額約37.77億元,主要用作候選藥物臨床開發和商業化、撥付建設新生產設施及還債等。上市聯席保薦人分別為大摩、摩通及華泰金控香港。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account